Loading company details...
Latest Form 4 (Sep 15, 2026): Jack Higgins (Chief Scientific Officer): Exercise/Conversion of 18,000 shares, $24.3K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Jack Higgins, Chief Scientific Officer | Exercise/Conversion | 18,000 | $24.3K |
| Aug 12, 2026 | Isaac Barchas | Sale | 10,125 | $264.0K |
| Aug 10, 2026 | Isaac Barchas | Sale | 20,840 | $543.1K |
| Aug 6, 2026 | Kinney Horn, CHIEF BUSINESS OFFICER | Exercise/Conversion | 50,366 | $650.7K |
| Jul 27, 2026 | Kinney Horn, CHIEF BUSINESS OFFICER | Grant/Award | 31,250 | n/a |
| Jul 27, 2026 | Philip Tsai, Chief Technical Officer | Grant/Award | 38,250 | n/a |
| Jul 27, 2026 | Sandra G. Stoneman, CHIEF LEGAL OFFICER & GC | Grant/Award | 38,250 | n/a |
| Jul 27, 2026 | Jack Higgins, Chief Scientific Officer | Grant/Award | 38,250 | n/a |
| Jul 27, 2026 | Max Rosett, Chief Financial Officer | Grant/Award | 47,250 | n/a |
| Jul 27, 2026 | Robert Lechleider, Chief Medical Officer | Grant/Award | 54,000 | n/a |